Trial Profile
Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix-IPV+HibTM) in Healthy Vietnamese Toddlers
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Oct 2023
Price :
$35
*
At a glance
- Drugs Hib-DTaP-poliovirus vaccine (Primary)
- Indications Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Mar 2013 Planned End Date changed from 1 Mar 2013 to 1 May 2013 as reported by ClinicalTrials.gov.